You are currently viewing the abstract.
View Full TextLog in to view the full text
AAAS login provides access to Science for AAAS members, and access to other journals in the Science family to users who have purchased individual subscriptions.
More options
Download and print this article for your personal scholarly, research, and educational use.
Buy a single issue of Science for just $15 USD.
Abstract
Each year, more than a half million people in the United States alone die from sepsis, a dire multisystem disease with highly inadequate treatment options. In a recent issue of Science, Puneet and colleagues provide compelling evidence that inhibiting sphingosine kinase 1—an enzyme that resides in immune cells and is activated by inflammatory signals—might have great potential as a therapy for septic shock.
Footnotes
-
Citation: L. A. J. O’Neill, Stopping sepsis by targeting sphingosine kinase 1. Sci. Transl. Med. 2, 36ps29 (2010).
- Copyright © 2010, American Association for the Advancement of Science
